Acute Myeloid Leukemia

Naeim, Faramarz; Rao, P. Nagesh

doi:10.1016/b978-0-12-370607-2.00011-9

Cited by 10 publications

(24 citation statements)

References 223 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal karyotypes have been described in 50 % of adult AML patients, with t(8;21)(q22;q22) approximately in 6 % adults with AML-M2 and associated with good prognosis [1][2][3]. Del(9q), described in AML is a rare uncommon karyotypic abnormality reported in very few patients in literature world wide.…”

Section: Discussionmentioning

confidence: 99%

“…Loss of such a small segment has not been reported earlier and possibly the genes in this region (not yet defined) may be critical for leukemogenesis in the absence of AML1 ETO rearrangement suggesting the operation of another pathway. AML normal cytogenetics involves testing for prognostic indicators FLT3, NPM1, CEBPA mutations [1][2][3]. Data on status of FLT3/NPM1/CEBPA mutations in the context of del 9q as the sole abnormality/in association with t(8;21)/ other karyotypic abnormalities with reference to loss of various segments in del 9q is sparse.…”

Section: Discussionmentioning

confidence: 99%

“…Conventional/molecular cytogenetic analysis plays an integral part of the diagnostic workup of AML patients having a direct impact on the choice of treatment and patient prognosis [3]. Interstitial deletion of the long arm of chromosome 9 (9q-) is a recurrent uncommon karyotypic abnormality described in very, very few patients world wide [4][5][6] including India [7] and has been described as the primary sole karyotypic abnormality/ or in association with recurrent abnormalities such as 8;21 translocation in AML M2 or very rarely in association with 15;17 translocation in AML M3.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Case of AML-M2 with Sole Interstitial Deletion in 9q Without AML1–ETO/Inv 16 Rearrangement and FLT3/NPMI Mutations

Devi

Ahmed

Mundada

et al. 2014

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Case of AML-M2 with Sole Interstitial Deletion in 9q Without AML1–ETO/Inv 16 Rearrangement and FLT3/NPMI Mutations

Devi

Ahmed

Mundada

et al. 2014

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

show abstract

“…Favorable prognosis is associated with the presence of Auer rods in M1-M4 and M2-M4Eo and adults with translocation 8;21. [124]…”

Section: Discussionmentioning

confidence: 99%

“…[3] Most AML have specific non-random, clonal chromosomal abnormalities associated with morphologically and clinically distinct subsets of the disease such as the well known 8;21 translocation in AML M2, 15;17 translocation in acute promyelocytic leukemia-M3 etc., with prognostic, and therapeutic importance. [14] Here we report a case of AML-M2 having a unique chromosomal abnormality the 11;18 translocation with new breakpoints.…”

Section: Introductionmentioning

confidence: 99%

A novel 11;18 translocation in a case of acute myeloid leukemia with maturation

Sandhya¹,

Ahmed²,

Khadke³

et al. 2012

Indian J Hum Genet

View full text Add to dashboard Cite

Acute myeloid leukemia with maturation (AML-M2) is associated with the 8;21 translocation. For the first time in an adult patient with AML-M2, a novel unbalanced translocation involving the short arm of chromosome 11 and long arm of chromosome18 with new breakpoints is presented. CD82 on band 11p11.2 and GATA 6 on 18q11.2 may play a role in the pathogenesis of de novo AML M2. The report with translocation (11;18)(p11.2;q11.2), as the sole cytogenetic abnormality provides more data on the leukemogenesis of de novo AML M2.

show abstract

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

et al. 2023

View full text Add to dashboard Cite

Lenalidomide-based regimens are commonly used for early relapse in patients with relapsed and/or refractory multiple myeloma (RRMM) receiving at least one prior line of therapy. In the absence of headto-head comparison, matching-adjusted indirect comparison (MAIC) was conducted to demonstrate e cacy and safety of isatuximab+car lzomib+dexamethasone (Isa-Kd) vs. daratumumab+lenalidomide+dexamethasone (Dara-Rd) in RRMM. Patient-level data from IKEMA trial (Isa-Kd, n=179) were matched to aggregate data from POLLUX (Dara-Rd, n=286). Hazard ratios (HR) and 95% con dence intervals (CI) for progression-free survival (PFS) and overall survival (OS) were generated by weighted Cox proportional hazard models. Odds ratios (OR), 95% CI, and p-value were calculated for ≥very good partial response (≥VGPR) and treatment-emergent adverse events (TEAEs). After matching, no signi cant differences were observed between Isa-Kd and Dara-Rd in baseline characteristics except for patients with >3 prior lines (0.0% vs. 4.9%). Isa-Kd showed signi cantly better PFS (HR [95% CI]: 0.46 [0.24-0.86]; p=0.0155), statistically non-signi cant improvement favoring Isa-Kd in OS (0.47 [0.20-1.09]; 0.0798), and ≥VGPR (OR [95% CI]: 1.53 [0.89-2.64]; p=0.1252) than Dara-Rd. Odds of occurrence were signi cantly lower for some all-grade and grade 3/4 TEAEs with Isa-Kd than Dara-Rd. These results support Isa-Kd as an e cacious treatment for early relapse in non-lenalidomide refractory patients.

show abstract

Acute Myeloid Leukemia

Cited by 10 publications

References 223 publications

A Case of AML-M2 with Sole Interstitial Deletion in 9q Without AML1–ETO/Inv 16 Rearrangement and FLT3/NPMI Mutations

A Case of AML-M2 with Sole Interstitial Deletion in 9q Without AML1–ETO/Inv 16 Rearrangement and FLT3/NPMI Mutations

A novel 11;18 translocation in a case of acute myeloid leukemia with maturation

Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma

Contact Info

Product

Resources

About